XML 28 R16.htm IDEA: XBRL DOCUMENT v3.4.0.3
Significant Customers and Concentrations of Risk (Tables)
 3 Months Ended
Mar. 31, 2016
Risks And Uncertainties [Abstract]  
Summary of Revenues by Customer Location

Revenues by customer location are summarized as follows:

 

  

 

Three Months Ended

 

 

 

March 31,

 

 

 

2016

 

 

2015

 

United States of America

 

$

10,570,606

 

 

$

6,762,776

 

Europe

 

 

1,567,341

 

 

 

1,471,416

 

Other

 

 

180,825

 

 

 

113,845

 

 

 

$

12,318,772

 

 

$

8,348,037

 

 
Summary of Significant Customers Comprising 10% or More of Total Revenue

Significant customers comprising 10% or more of total revenue are as follows:

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2016

 

 

2015

 

Teva

 

$

6,485,850

 

 

$

2,332,815

 

McKesson (1)

 

 

1,709,294

 

 

 

1,899,705

 

Ferring

 

 

1,658,622

 

 

 

1,471,416

 

LEO Pharma

 

 

—

 

 

 

857,143

 

AmerisourceBergen(1)

 

 

1,147,086

 

 

 

875,145

 

 

 

(1)

Represents estimated revenue based on OTREXUP™ shipments, a portion of which has not been recognized as revenue but is recorded in deferred revenue at the end of each period as discussed in Note 2 to the Consolidated Financial Statements.